Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials. Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed. Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug. Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer. Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape. The Ga-PSMA-11 and Ga-P16-093 PSMA-PET tracers are useful tools for surgical guidance in prostate cancer. iQuest is the first AI-powered platform of its kind to aid in the development of personalized prostate cancer care plans. This use of molecular MRI with targeted agents can enhance tumor margin detection and inform treatment decision-making.